Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study

Table 4 Risk factors predicting progression-free survival in HCC patients with MVI who received one-shot CDDP plus RT

Parameter	Univariate analysis	Multivariate analysis
Parameter	p value	OR	95% CI	p value
Age (≥ 65/ < 65 years)	0.753
Gender (female/male)	0.269
Etiology (with viral hepatitis/without viral hepatitis)	0.991
ECOG-PS (0/ ≥ 1)	0.799
Albumin (≥ 3.5/ < 3.5 g/dL)	0.838
Prothrombin consumption test (≥ 70%/ < 70%)	0.619
Child–Pugh score (≥ 6/5)	0.375
mALBI grade (≥ 2b/ ≤ 2a)	0.505
Diameter of main tumor (≥ 70/ < 70 mm)	0.479
Number of tumors in the liver (≥ 4/ < 4)	0.201
Relative tumor volume in the liver (≥ 50%/ < 50%)	0.009	2.79	1.247–6.243	0.013
Vp (3/4)	0.949
Vv (with/without)	0.713
Extrahepatic spread (with/without)	0.304
Alpha-fetoprotein (≥ 400/ < 400 ng/mL)	0.135
Des-γ-carboxy prothrombin (≥ 400/ < 400 mAU/mL)	0.906
Best response of MVI (CR or PR/SD or PD)	0.132

Univariate and multivariate analysis of risk factor of overall survival in HCC patients with MVI who received one-shot CDDP chemotherapy via HAI plus RT. HCC hepatocellular carcinoma; MVI macrovascular invasion; CDDP cisplatin; RT radiation therapy; OR odds ratio; CI confidence interval; ECOG-Performance Status Eastern Cooperative Oncology Group Performance Status; ALBI score = log₁₀([total-bilirubin(mg/dL)]*17.1*0.66 − [albumin(g/dL)]*10*0.085; mALBI grade 1: 2a: 2b: 3 = ALBI score ≤ − 2.6: > − 2.6 to < − 2.27: ≥ − 2.27 to ≤ − 1.39: > − 1.39; Vp portal vein invasion; Vv venous invasion; SD stable disease; PD progressive disease; CR complete response; PR partial response; HAI hepatic arterial infusion

ISSN: 1471-230X